drugset / Trial / NCT07439250

A Study of Olomorasib (LY3537982) in Healthy Participants

NCT07439250

Phase 1 Completed 15 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.

Timeline

Start
2026-03-02
Primary completion
2026-04-17
Completion
2026-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule Oral
Subject Olomorasib Small molecule Oral

Indications

No indication recorded.